Maxim Group analyst Jason McCarthy downgrades 9 Meters Biopharma (NASDAQ:NMTR) from Buy to Hold.
4DMT Presents Interim Data From 4D-310 INGLAXA Phase 1/2 Clinical Trials For Fabry Disease Cardiomyopathy At WORLDSymposium 2024
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all
